Autism spectrum disorder affects millions of children worldwide and poses lifelong challenges. Current treatments often fail to address its root causes and can cause significant side effects. Mercè Pallàs, from the Faculty of Pharmacy and Food Sciences of the University of Barcelona and the Institute of Neurosciences (UBneuro), is leading a project entitled
Preclinical development of a first-in-class treatment for autism spectrum disorder
whose main aim is to develop a drug that improves areas of the brain involved in social interaction and repetitive behaviours — two core symptoms of autism. This project is funded by the 2025 call of the CaixaImpulse programme (La Caixa Foundation).
More information https://web.ub.edu/en/web/actualitat/w/caixaimpulse-autism-treatment
